Parenteral Drugs (India) Performance
Fundamentals of Parenteral Drugs (India)
|P/E Ratio (TTM)||NA|
|Debt to Equity||-0.13|
Financials of Parenteral Drugs (India)
|Jun 2021||Sep 2021||Dec 2021||Mar 2022|
|Profit before tax||-41.05||-43.05||-44.23||19.21|
|EPS in Rs||-10.74||-11.28||-11.58||-9.53|
About Parenteral Drugs (India)
Parenteral Drugs (India) Ltd is an India-based pharmaceutical company. The company develops, manufactures, and markets a range of pharmaceutical products in India. Their products include solid and liq ... uid orals, such as antibiotics and anti-bacterial, anti-ulcerant, analgesics/anti-inflammatory, multivitamins and minerals, anxiolyic , antiprotozoal, anticold, anthelmintic, anti-histaminic, muscle relaxant, cardiac, antidiabetic, cough syrup, appetite enhancer and injections. The company produces various therapeutic segments of In-Vitro (I V) Fluids, such as electrolytes, antibacterial, energy replenisher, irrigation solution, osmotic diuretic, dialysis solution. They also produce 400-milligram Ciprofloxacin infusion in 200 milliliter with 5% dextose. Apart from the single dose dispensers, the company has also launched multi-dose eye/ ear drops in plastic containers. The dispensers are made using the form-fill-seal technology. Parenteral Drugs (India) Ltd was incorporated in the year 1983 as a private limited company. In the year 1989, the company established their first unit to manufacture I V Fluids in Polypropylene containers with a capacity of 18 lakh bottles per annum. In March 1994, the company was converted into a public limited company. In September 1994, the company came out with a public issue at a premium of Rs 80, aggregating Rs 7.03 crore, to part-finance their Rs 8.97crore expansion. During the year 1994-95, the company set up a joint venture unit in Ukraine for manufacture of a wide range of pharmaceuticals. In addition, they set up a unit for the manufacture of I V Fluids at Jalandhar in Punjab. During the year 1997-98, the company purchased 100% equity of the Parenteral Drugs International Ltd and made it a wholly owned subsidiary of the company. They also purchased 50% equity in Parental Drugs (Punjab) Ltd. During the year 1999-2000, the company was awarded ISO 9002 Certification as a symbol of quality products. During the year 2003-04, the company installed Injections with the production capacity of 516 lakh numbers. During the year 2005-06, the company increased the production capacity of I V Fluid Transfusion by 45,000,000 Nos to 120,000,000 Nos. In addition, they set up a plant for manufacturing pharmaceutical products at Baddi in Himachal Pradesh. During the year 2006-07, the company increased the production capacity of Tablets/ Capsules by 1,125,000,000 Nos, Ampoules by 90,000,000 Nos and Injections 56,400,000 Nos. During the year 2007-08, they increased the production capacity of Large Volume by 30,000,000 Nos and Ampoules by 95,000,000 Nos. The Scheme of Amalgamation was sanctioned by the Hon'ble High Court of Judicature at Bombay vide its Order dated 12th October, 2009. Under the scheme of amalgamation, M/s. PFL Holdings Private Limited and M/s. Goa Holdings (India) Private Limited amalgamated with the Company and consequently, M/s.Punjab Formulations Limited and M/s.Goa Formulations Limited became wholly-owned subsidiaries of the Company with effect from 1st November, 2008. The Company incorporated a wholly-owned subsidiary in Kazakhstan in the name of 'Parenteral Drugs Kazakhstan' to undertake the business of manufacturing of pharmaceutical products during 2008. In 2009, the Company launched products comprised of Falcistar and Merogol for Injections and tablets/ capsules like Azimist and Megastar. It launched the products under the oncology (anti-cancer) segment comprising of Fludapar, Trexopar, Mindro and Ifoparwith Mesna. During 2009-10, Company converted 12,00,000 warrants into equity shares of Rs. 10/-each, which were issued by way of preferential allotment on 24th August, 2009, which were allotted to M/s.Mahaganpati Investments Private Limited, a Company under Promoter Category. During FY 2010-11, 10 new products such as GRASIPAR PFS, LEUCOPAR-50 INJECTION, PACOFF EXPECTORANT, PIDIMOL IV, 5 FU-PAR INJECTION, BOTEPAR INJECTION, ERLOPAR TABLETS, TEGNID INJECTION, CEFACE CV TABLETS, ERLOPAR TABLETS, ANTOXY-2 SYRUP and TAMOLGAN IV were introduced in the market. In 2014, Punjab Formulations Limited, a wholly owned subsidiary ceased to be in existence as the said Company was amalgamated with Infutec Healthcare Limited (Formerly: Goa Formulations Limited), a wholly owned subsidiary of the Company w.e.f. 12 September, 2014 vide Order of the Honorable High Court of Bombay Judicature. During year 2015-16, Company disinvested equity investment in two subsidiary companies namely Parentech Healthcare Limited and Parenteral Surgicals Limited. During 2016-2017, the Company disinvested from the equity shares held in its 2 subsidiary companies namely Abhay Drugs Limited and Anjaney Pharmaceuticals Limited. During the year 2018-19, Infutec Healthcare Limited, an erstwhile wholly owned subsidiary, ceased to be a subsidiary of company w.e.f 10 July, 2018. Read More
|Stocks||Market Cap (cr)||Market Price (₹)||52 Week Low-High (₹)|
|Supriya Lifescience Ltd||₹2,344.06||
|281.1 - 294.35|
|Celestial Biolabs Ltd||₹4.56||
|1.75 - 1.8|
|JFL Life Sciences Ltd||₹47.40||
|43.1 - 43.85|
|Procter & Gamble Health Ltd||₹8,541.86||
|5110 - 5178.5|
|Veerhealth Care Ltd||₹35.74||
|26 - 26|
What is the Share price of Parenteral Drugs (India) (PDPL)?
Can I buy Parenteral Drugs (India) (PDPL) shares?
How do I buy Parenteral Drugs (India) (PDPL) from Angel One?
- Direct investment: You can buy Parenteral Drugs (India) (PDPL) shares by opening a Demat account with Angel One.
- Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Parenteral Drugs (India) (PDPL) shares.